• Publications
  • Influence
Secondary progressive in contrast to relapsing‐remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T‐cell function and FOXP3 expression
Accumulating evidence indicates an immunosuppressive role for CD4+CD25+ regulatory T cells (Tregs) in autoimmune diseases. Although an impaired Treg function in patients with relapsing‐remittingExpand
Natural history of multiple sclerosis with childhood onset.
BACKGROUND The course and prognosis of childhood-onset multiple sclerosis have not been well described. METHODS We used data from 13 adult neurology departments affiliated with the EuropeanExpand
Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party.
To specify the incidence and risk factors for secondary autoimmune diseases (ADs) after HSCT for a primary AD, we retrospectively analyzed AD patients treated by HSCT reported to EBMT from 1995 toExpand
CCR2 defines in vivo development and homing of IL-23-driven GM-CSF-producing Th17 cells
IL-17-producing helper T (Th17) cells are critical for host defense against extracellular pathogens but also drive numerous autoimmune diseases. Th17 cells that differ in their inflammatory potentialExpand
Mitochondrial mutations of Leber's hereditary optic neuropathy: a risk factor for multiple sclerosis
Abstract Multiple sclerosis (MS) and Leber's hereditary optic neuropathy (LHON) have been found to occur in combination. Based on an extensive literature search and on a clinical analysis of 55 LHONExpand
Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15
Aim An exploratory study of the relationship between cumulative exposure to subcutaneous (sc) interferon (IFN) β-1a treatment and other possible prognostic factors with long-term clinical outcomes inExpand
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS
Background:Delayed-release dimethyl fumarate (DMF), indicated for the treatment of patients with relapsing-remitting multiple sclerosis (MS), is a disease-modifying therapy with potentialExpand
Clinical characteristics and long term prognosis in early onset multiple sclerosis
The clinical features, disease course and long term prognosis of early onset multiple sclerosis (EOMS) are variable. A preponderance of female sex, a high incidence of visual and brainstem symptomsExpand
Allogeneic bone marrow transplantation in models of experimental autoimmune encephalomyelitis: evidence for a graft-versus-autoimmunity effect.
Autologous hematopoietic stem cell transplantation (HSCT) is being explored in the treatment of severe multiple sclerosis (MS), and is based on the concept of "resetting" the immune system. The useExpand
Autologous and allogeneic hematopoietic stem cell transplantation for Multiple Sclerosis: Perspective on mechanisms of action
Multiple Sclerosis (MS) is a frequent demyelinating immune-mediated disease of the central nervous system (CNS) that affects principally young adults and leads to severe physical and cognitiveExpand
...
1
2
3
4
5
...